Successful targeting of activating mutations in the KIT receptor tyrosine kinase with imatinib mesylate for gastrointestinal stromal tumor (GIST) illustrates how this approach can potentially change outcomes even for notoriously chemotherapy-resistant sarcoma subtypes8, 9. Here, KIT is linked to gastrointestinal stromal tumor.